DistantNews
Support us
🇹🇼 Taiwan /Health & Science

Anli Xirong-KY Aims for Innovation Board Listing, Focuses on New Alzheimer's Treatment Direction

From Liberty Times · () Chinese

Translated from Chinese, summarized and contextualized by DistantNews.

At a glance

News Named sources New plan
  • Taiwanese biotech firm Anli Xirong-KY is preparing to list on the innovation board this year.
  • The company is developing a new Alzheimer's drug, Enrupatinib (EI-1071), which has shown potential in reducing neuroinflammation.
  • Researchers believe targeting neuroinflammation is a key strategy for new Alzheimer's treatments, potentially complementing existing therapies.

Anli Xirong-KY, a Taiwanese company listed on the emerging stock market, is gearing up for a listing on the innovation board this year. The company recently presented key interim data from its Phase II clinical trial for Enrupatinib (EI-1071), an experimental drug for Alzheimer's disease.

In recent years, the scientific community has gradually realized that even if amyloid plaques in the brain are cleared, if the "microenvironment" of neuroinflammation is not changed, nerve cells will still be continuously damaged.

— Chen Hong-kaiChairman of Anli Xirong-KY, explaining the evolving understanding of Alzheimer's disease.

Chairman Chen Hong-kai explained that scientific understanding of Alzheimer's is evolving. While clearing amyloid plaques was once the primary focus, researchers now recognize that neuroinflammation plays a critical role. In the disease process, microglia, the brain's immune cells, become overactive. They shift from clearing waste to releasing inflammatory factors, which damages nerve cells and accelerates cognitive decline.

Chen highlighted that Enrupatinib shows promise in reducing biomarkers of neuroinflammation, supporting its mechanism of action in modulating microglial activity. In a precisely selected patient group, the drug achieved an 80% response rate. Furthermore, neuroinflammation signals in relevant brain regions decreased by over 30% on average.

Enrupatinib has shown potential in reducing biomarkers of neuroinflammation in the Phase II clinical trial, further supporting its pharmacological action in regulating microglial activity.

— Chen Hong-kaiDiscussing the interim data from the Enrupatinib clinical trial.

These clinical findings suggest that modulating neuroinflammation is a viable therapeutic approach for Alzheimer's. Chen emphasized that Enrupatinib could serve as an important complementary treatment to existing therapies targeting amyloid or tau proteins.

The clinical findings of Enrupatinib confirm the feasibility of neuroinflammation modulation as a disease-modifying therapy and can serve as an important complementary pathway to existing therapies that inhibit amyloid or tau proteins.

— Chen Hong-kaiHighlighting the significance of the drug's potential.
DistantNews Editorial

Originally published by Liberty Times in Chinese. Translated, summarized, and contextualized by our editorial team with added local perspective. Read our editorial standards.

More Stories

From Our Blog